ReviewInternational journal of molecular sciences2020
Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 1 synthesis or guideline pooled it.
- ZnO-Based Nanoparticles for Targeted Cancer Chemotherapy and the Role of Tumor Microenvironment: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Single-cell and longitudinal transcriptomics-guided engineering of FZD1-targeting precision nanotherapy against osteosarcoma cancer stem cells.Bioactive materials · 2026Article
- Advanced nanocatalytic medicine for genitourinary diseases: Reactive oxygen modulation, precision therapeutics, and clinical translation.Materials today. Bio · 2026Article
- Targeted Strategies for Treatment of Colorectal Cancer: Exploring the Use of Aptamers and Gold Nanoparticles.Molecules (Basel, Switzerland) · 2026Review
- Chitosan in Modern Pharmacotherapy: Chitosan Nanoparticles and Delivery Systems.Pharmaceutics · 2026Review
- Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation.Signal transduction and targeted therapy · 2026Review
- Injectable Hydrogels for Breast Cancer Therapy: From Tumor Microenvironment-Responsive and Actively Targeted Drug Delivery to Immunotherapy and Theranostics.Pharmaceutics · 2026Review
- Bioengineered Silver Nanoparticles: Next-Generation Biogenic Synthesis Strategies for Precision Biomedical Applications.Bioengineering (Basel, Switzerland) · 2026Review
- Aptamer-Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap.Small science · 2026Article
- Ponatinib confers adult human cardiomyocyte toxicity via inhibition of AKT signaling.Physiological reports · 2026Article
- Nanomaterial-Based Therapeutic Delivery: Integrating Redox Biology, Genetic Engineering, and Imaging-Guided Treatment.Antioxidants (Basel, Switzerland) · 2026Review
- The multifaceted roles of the ACSL family in cancer: Metabolic reprogramming, ferroptosis regulation and tumour immune microenvironment remodelling.Clinical and translational medicine · 2026Review
- Fabrication and Functional Modification Strategies of Squid Ink-Derived Nanoparticles: From Natural Melanin to Multifunctional Biomaterials.Marine drugs · 2026Review
- Interplay between microRNAs and TGF-β signaling in T cells: implications for Th9 differentiation and immune pathogenesis.Frontiers in immunology · 2026Review
- Aptamer-Mediated Dual-Loaded Liposomal Nanosystem for Synergistic Therapy in Hepatocellular Carcinoma via mTOR/HIF-1α/VEGF Pathway.International journal of nanomedicine · 2026Article
- Artificial Intelligence-Driven SELEX Design of Aptamer Panels for Urinary Multi-Biomarker Detection in Prostate Cancer: A Systematic and Bibliometric Review.Biomedicines · 2025Review
- Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.Molecular cancer · 2025Review
- Developing Nanoparticle-Based Therapeutics for Targeting the Microenvironment in Obesity-Induced Endometrial Cancer.Cellular and molecular bioengineering · 2025Article
- Nanocarrier-Based Systems for Targeted Delivery: Current Challenges and Future Directions.MedComm · 2025Review
- Aptamer-based applications in delivering cancer gene therapies and beyond: state of the art and the missing links to clinical translation.Advanced drug delivery reviews · 2025Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Using nanoparticles to carry and delivery anticancer drugs holds much promise in cancer therapy, but nanoparticles per se are lacking specificity. Active targeting, that is, using specific ligands to functionalize nanoparticles, is attracting much attention in recent years. Aptamers, with their several favorable features like high specificity and affinity, small size, very low immunogenicity, relatively low cost for production, and easiness to store, are one of the best candidates for the specific ligands of nanoparticle functionalization. This review discusses the benefits and challenges of using aptamers to functionalize nanoparticles for active targeting and especially presents nearly all of the published works that address the topic of using aptamers to functionalize nanoparticles for targeted drug delivery and cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.